On February 18, 2025, Biogen Inc. and Stoke Therapeutics, Inc. announced a collaboration for the development and commercialization of zorevunersen, a potential first-in-class disease-modifying medicine for Dravet syndrome. This agreement grants Biogen exclusive commercialization rights for zorevunersen in all territories outside the United States, Canada, and Mexico, while Stoke retains rights in those regions.
Under the terms of the collaboration, Stoke will receive an upfront payment of $165 million. Additionally, Stoke is eligible to receive up to $385 million in development and commercial milestone payments, along with tiered royalties ranging from low double digits to high teens on potential net sales in Biogen's territory. The parties will share external clinical development costs, with Biogen contributing 30% and Stoke 70%.
Zorevunersen is an investigational antisense oligonucleotide (ASO) targeting the SCN1A gene, which is the underlying cause of most cases of Dravet syndrome, a severe genetic epilepsy. The pivotal Phase 3 EMPEROR study of zorevunersen is on track to initiate in the second quarter of 2025, with a data readout anticipated in the second half of 2027. Zorevunersen has already received FDA Breakthrough Therapy Designation, highlighting its potential to address significant unmet treatment needs for the estimated 38,000 people living with Dravet syndrome in key markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.